<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549666</url>
  </required_header>
  <id_info>
    <org_study_id>D1050246</org_study_id>
    <nct_id>NCT00549666</nct_id>
  </id_info>
  <brief_title>A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects</brief_title>
  <acronym>OC-DDI</acronym>
  <official_title>A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, drug, drug, interaction study between Lurasidone HCl and Ortho-tri cyclen
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Lurasidone 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ortho Tri-Cyclen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone 40 mg</intervention_name>
    <description>Lurasidone 40 mg days 12-21 once daily</description>
    <arm_group_label>Lurasidone 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 40 mg</intervention_name>
    <description>Placebo 40 mg once daily during treatment period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ortho Tri-Cyclen</intervention_name>
    <description>Ortho Tri-Cyclen during 28-day lead in period</description>
    <arm_group_label>Ortho Tri-Cyclen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is female between 18 and 40 years of age

          -  Female subjects of reproductive potential will demonstrate a negative serum β-human
             chorionic gonadotropin level consistent with the non-gravid state at the screening
             visit

          -  Subject agrees to take the triphasic oral contraceptive, Ortho Tri-Cyclen™, throughout
             the study.

          -  Subject has a history of regular menstrual periods with no substantial breakthrough
             bleeding episodes while taking Ortho Tri-Cyclen™.

          -  Subject has a body mass index that is &lt; 33 kg/m2 (see Appendix 1).

          -  Subject is judged to be in good health

          -  Subject must have a negative hepatiti and HIV antibody at screening.

          -  Subject has no clinically significant abnormality on screening ECG.

        Exclusion Criteria:

          -  Subject has a history of major GI abnormalities/peptic ulceration, hematological,
             genitourinary, cardiovascular (including hypertension), renal, hepatic, pulmonary,
             psychiatric, endocrine (including diabetes) or metabolic (including glaucoma),
             neurologic or cerebrovascular disease, or any history of cancer.

          -  Subject has systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90
             mm Hg at screening.

          -  Subject has a history of any chronic and/or active hepatic disease including
             elevations of serum transaminases, hepatitis, biliary tract disease, or a history of
             any gastrointestinal surgery.

          -  Subject has any other acute or chronic medical or psychiatric condition that, in the
             opinion of the investigator, would limit the patient safety or confound the results of
             the study.

          -  Subject has an ECG at screening with PR &gt; 240 msec; QRS complex &gt; 120 msec; QTcB &gt;
             450; or any significant morphologic changes other than nonspecific T-wave changes.

          -  Subject is currently a user of any illicit drugs (including &quot;recreational use&quot;)
             including marijuana, or has recently used illicit drugs, or has a history of drug or
             alcohol dependence in the past year or abuse within the last 3 months.

          -  Subject consumes excessive amounts of alcohol

          -  Subject has had surgery within last 12 weeks, donated a unit of blood (within 4
             weeks), or participated in another clinical study within 30 days of screening.

          -  Subjects with hypertension, hyperlipidemia, and diabetes should also be excluded. (See
             package circular under &quot;Contraindications&quot;)

          -  Subject has clinically significant abnormalities at screening clinical examination or
             laboratory safety tests

          -  Subject has a prolactin level of over 200 ng/mL at screening.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Global Clinical Pharmacology, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2007</study_first_submitted>
  <study_first_submitted_qc>October 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2007</study_first_posted>
  <last_update_submitted>September 12, 2011</last_update_submitted>
  <last_update_submitted_qc>September 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OC DDI</keyword>
  <keyword>lurasidone</keyword>
  <keyword>Latuda</keyword>
  <keyword>schizophenia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

